Medical Device | March 22, 2022
Thermo Fisher Scientific to showcase global innovation at DCAT Week 2022
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
Subscribe To Our Newsletter & Stay Updated
